deferasirox has been researched along with Myelodysplastic Syndromes in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (20.00) | 29.6817 |
| 2010's | 70 (73.68) | 24.3611 |
| 2020's | 6 (6.32) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M | 1 |
| Antonio Russo, M; Frustaci, A; Galea, N; Labbadia, G; Menafra, V; Verardo, R | 1 |
| Han, B; Zhang, R | 1 |
| Abáigar, M; Arrizabalaga, B; de Paz, R; Del Rey, M; Díez-Campelo, M; Erquiaga, S; González, T; Hernández-Rivas, JM; López, DA; Lumbreras, E; Martín, AÁ; Sánchez, JMH; Vicente, AER | 1 |
| Angelucci, E; Dong, X; Garcia-Manero, G; Ghosh, J; Greenberg, P; Hou, M; Izquierdo, M; Li, J; Montano Figueroa, EH; Rodriguez, MG; Wu, D | 1 |
| Bowen, D; Coulthard, HC; Culligan, D; Das-Gupta, E; Jackson, A; Killick, S; Pennell, DJ; Porter, J; Yap, C | 1 |
| Angelucci, E; Balleari, E; Breccia, M; Clissa, C; Cortelezzi, A; Fenu, S; Finelli, C; Levis, A; Mansueto, G; Marziano, G; Maurillo, L; Milella, MR; Musto, P; Niscola, P; Poloni, A; Ricco, A; Rivellini, F; Sanna, A; Santini, V; Scapicchio, D; Simeon, V; Tarantini, G; Venditti, A; Villani, O; Voso, MT | 1 |
| Rose, C | 1 |
| Leitch, HA; Wong, SA | 1 |
| Gattermann, N | 1 |
| Belli, AA; Dere, Y; Karakus, V; Polat, AK | 1 |
| Komrokji, RS; Shammo, JM | 1 |
| Aydinok, Y; Kattamis, A; Taher, A | 1 |
| Chang, CS; Chang, MC; Chang, TK; Chen, TY; Chen, YC; Chiou, TJ; Hwang, WS; Ko, BS; Lin, SF; Lu, YC; Yeh, SP | 1 |
| Belhoul, K; Bobbili, P; Bruederle, A; Duh, MS; Han, J; Huang, V; Kouraklis, A; Origa, R; Perrotta, S; Porter, JB; Taher, AT | 1 |
| Angelucci, E; Beltrami, G; Bontempi, K; Borin, L; Cotugno, F; Di Tucci, AA; Fazi, P; Finelli, C; Piciocchi, A; Quaresmini, G; Riva, M; Sargentini, V; Vallisa, D; Vignetti, M | 1 |
| Aires-Mejía, I; Albarrán, B; Alonso, JM; Caballero-Berrocal, JC; Del Cañizo, C; Díez-Campelo, M; García-Martín, L; Hernández-Hernández, Á; Jiménez-Solas, T; López-Cadenas, F; Muntión, S; Ortega, R; Redondo, AM; Sánchez-Guijo, F | 1 |
| Alimena, G; Breccia, M | 1 |
| Kami, M; Kobayashi, K; Nishikawa, Y; Okuda, S; Takebayashi, C; Tanimoto, T | 1 |
| Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J | 1 |
| Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| de Witte, T | 1 |
| Chung, J; Jang, JH; Jo, DY; Kim, HJ; Lee, JH; Lee, JW; Yoon, SS | 1 |
| Cheong, JW; Chung, J; Hyun, MS; Jo, DY; Joo, YD; Jung, CW; Kim, BS; Kim, CS; Kim, HJ; Kim, HY; Lee, JH; Lee, KH; Min, YH; Park, CY; Park, HS; Seong, CM; Shim, H; Sohn, SK; Yoon, HJ; Yoon, SS | 1 |
| Tohyama, K | 1 |
| Alimena, G; Angelucci, E; Borin, L; Caocci, G; Cilloni, D; Di Tucci, AA; Fazi, P; Fenu, S; Finelli, C; Latte, G; Molteni, A; Piciocchi, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Storti, S; Tura, S; Vallisa, D; Vignetti, M; Volpe, A; Voso, MT | 1 |
| Merkel, DG; Nagler, A | 1 |
| Clissa, C; Finelli, C; Stanzani, M | 1 |
| Hayakawa, F; Naoe, T; Tomita, A | 1 |
| Alimena, G; Angelucci, E; Borin, L; Cilloni, D; Cottone, F; Di Tucci, AA; Efficace, F; Fenu, S; Finelli, C; La Nasa, G; Mandelli, F; Molteni, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Volpe, A; Voso, MT | 1 |
| Banerjee, A; Bentley, M; Bird, R; Forsyth, C; Grigg, A; Grigoriadis, G; Kellner, S; Mifsud, NA; Motum, P; Opat, S; Szer, J; Tam, C | 1 |
| Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK | 1 |
| Alimena, G; Aloe Spiriti, MA; Breccia, M; Buccisano, F; Fenu, S; Maurillo, L; Tafuri, A; Voso, MT | 1 |
| Bae, SH; Chung, JS; Hyun, MS; Joo, YD; Kim, H; Kim, HG; Kim, IH; Kim, SH; Kim, YS; Kwon, KY; Lee, GW; Lee, HS; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, KT; Ryoo, HM; Sohn, SK | 1 |
| Aloe Spiriti, MA; Breccia, M; Buccisano, F; Criscuolo, M; D'Addosio, A; Fenu, S; Fragasso, A; Latagliata, R; Maurillo, L; Musto, P; Niscola, P; Piccioni, AL; Refrigeri, M; Tatarelli, C; Trapè, G; Venditti, A; Voso, MT | 1 |
| Agaoglu, L; Glaser, S; Kilinç, Y; Kohgo, Y; Lim, LC; Miyamura, K; Urabe, A; Wang, C; Warzocha, K; Wiktor-Jedrzejczak, W | 1 |
| Baer, MR; Davidoff, AJ; Friedmann, E; Gore, SD; Hendrick, F; Paley, C; Sasane, M; Zeidan, AM | 1 |
| Angelucci, E; Breccia, M; Gattermann, N; Hofmann, WK; Nolte, F; Santini, V; Vey, N | 1 |
| Escudero-Vilaplana, V; Garcia-Gonzalez, X; Osorio-Prendes, S; Romero-Jimenez, RM; Sanjurjo-Saez, M | 1 |
| Bruch, HR; Dencausse, Y; Heßling, J; Michl, G; Schlag, R; Schneider-Schranz, C; Schulte, C; Skorupa, A; Tesch, H; Wolf, S | 1 |
| Arboscello, E; Biale, L; Del Corso, L; Filiberti, R; Parodi, EL; Russo, R | 1 |
| Avilia, S; Catalano, L; Cerchione, C; Cerciello, G; Della Pepa, R; Pane, F; Picardi, M; Pugliese, N | 1 |
| Cortoos, A; Goh, AS; Huang, V; Kattamis, A; Kourakli, A; Merino Herranz, R; Origa, R; Perrotta, S; Porter, JB; Ruffo, GB; Taher, AT; Weill, M | 1 |
| Hata, T; Ishikawa, T; Kato, J; Kondo, M; Miyazawa, K; Mori, H; Nakao, S; Ohyashiki, K; Omine, M; Ozawa, K; Rojkjaer, L; Taniguchi, J; Tanii, H; Tatsumi, Y; Urabe, A | 1 |
| Brosnahan, G; Gokden, N; Swaminathan, S | 1 |
| Dinter, D; Dorn-Beineke, A; Hastka, J; Hehlmann, R; Leismann, O; Lutz, K; Metzgeroth, G; Schultheis, B | 1 |
| Arruga, F; Cilloni, D; Messa, E; Messa, F; Roetto, A; Saglio, G | 1 |
| Capalbo, S; Franzese, MG; Palumbo, G; Spinosa, G | 1 |
| Baumgartner, C; Nösslinger, T; Pfeilstöcker, M; Sperr, WR; Valent, P; Wimazal, F | 1 |
| Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Taher, A | 1 |
| Stone, RM; Tefferi, A | 1 |
| Cernik, C; Haller, N; Mostow, EN | 1 |
| Arrizabalaga, B; Del Cañizo, C; Remacha, AF; Sanz, G; Villegas, A | 1 |
| Cappellini, MD; Taher, A | 1 |
| HATANO, K; MATSUYAMA, T; MORI, M; MUROI, K; NAGAI, T; OKABE, H; OMORI, T; OZAWA, K; QZAKI, K; SUZUKI, T; TOSHIMA, M; UEDA, M; UEHARA, E | 1 |
| Schmid, M | 1 |
| Fujita, T; Haba, R; Nishiuchi, T; Ohnishi, H; Okutani, Y; Yoshida, K | 1 |
| Alati, C; Marino, A; Nobile, F; Oliva, EN; Praticò, G; Ronco, F | 1 |
| Fausel, CA | 1 |
| Fibach, E; Ghoti, H; Grisariu, S; Merkel, D; Perez-Avraham, G; Rachmilewitz, EA | 1 |
| Domokos, G; Fenaux, P; Finelli, C; Ganser, A; Gattermann, N; Guerci-Bresler, A; Habr, D; Porta, MD; Rose, C; Roubert, B; Schmid, M; Taylor, K; Vassilieff, D | 1 |
| Alberti, D; Arruga, F; Bracco, E; Carturan, S; Cilloni, D; Defilippi, I; Greco, E; Maffè, C; Messa, E; Messa, F; Pautasso, M; Pellegrino, RM; Roetto, A; Rosso, V; Rotolo, A; Saglio, G; Zanone, C | 1 |
| Cabantchik, ZI; Glynos, T; Greenberg, PL; Koller, CA; Paley, C; Schiffer, C; Warsi, G | 1 |
| Alimena, G; Breccia, M; Cannella, L; Loglisci, G; Salaroli, A; Santopietro, M | 1 |
| Leitch, HA | 1 |
| Bozkaya, D; Li, Q; Migliaccio-Walle, K; Miranda, E; Oliver, N; Tolley, K | 1 |
| Tefferi, A | 2 |
| Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G | 1 |
| Bianchino, G; Bochicchio, GB; D'Auria, F; Grieco, V; Guariglia, R; Lerose, R; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O | 1 |
| Fibach, E; Ganz, T; Ghoti, H; Gordana, O; Rachmilewitz, EA; Westerman, M | 1 |
| Patel, P; Rondelli, D; Sweiss, K | 1 |
| Almeida, A; Angelucci, E; Beris, P; Guerci-Bresler, A; Hofmann, WK; Macwhannell, A; Muus, P; Nolte, F; Porter, J; Schumann, C; Selleslag, D; Sliwa, T; Xicoy, B | 1 |
| Blumenstengel, K; Gattermann, N; Germing, U; Goebeler, M; Groschek, M; Jarisch, A; Junkes, A; Leismann, O; Losem, C; Procaccianti, M; Schlag, R | 1 |
| Berard, F; Martin, O; Nicolas, JF; Rozieres, A; Said, BB | 1 |
| Miyazaki, Y | 1 |
| Kato, J; Matsuki, E; Matsumoto, K; Nakaya, A; Okamoto, S; Yamane, A | 1 |
| Della Porta, M; Fenaux, P; Finelli, C; Gattermann, N; Guerci-Bresler, A; Habr, D; Marcellari, A; Rose, C; Roubert, B; Schmid, M; Stadler, M; Taylor, K; Vassilieff, D | 1 |
| Bhatia, R; Forman, S; Li, L; Lin, A; Meng, Z; Pullarkat, V; Sehgal, A | 1 |
| Araki, H; Hara, T; Moriwaki, H; Oyama, M; Tsurumi, H; Yoshikawa, T | 1 |
| Baer, MR; Besa, E; Esposito, J; Feigert, J; List, AF; Martinez-Lopez, N; Paley, C; Raza, A; Steensma, DP | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Fibach, E; Rachmilewitz, EA | 1 |
| Arnold, L; Kurtin, SE; Lindroos-Kolqvist, P; Shah, J; Tinsley, S | 1 |
| Hayashi, T; Iyama, S; Kaneko, Y; Kato, J; Kawano, Y; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Ono, K; Sato, T; Sato, Y; Takada, K; Takimoto, R | 1 |
| Baier, M; Gattermann, N; Giagounidis, A; Haase, D; Höchsmann, B; Hofmann, WK; Junkes, A; Leismann, O; Lübbert, M; Lück, A; Nolte, F; Platzbecker, U; Schrezenmeier, H; Schumann, C; Taupitz, M | 1 |
| Maekawa, T; Yoshioka, S | 1 |
| Ruivard, M | 1 |
| Braulke, F; Haase, D; Hartmann, J; Konietschke, F; Maas, JH; Sinzig, U; Wulf, G | 1 |
| Greenberg, PL | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Barton, JC | 1 |
| Alberti, D; Alimena, G; Cappellini, MD; Cario, H; Cazzola, M; Cunningham, MJ; Debusscher, L; Della Porta, M; Ford, JM; Forni, GL; Galanello, R; Gathmann, I; Gattermann, N; Giardina, P; Greenberg, P; Jeng, M; Kwiatkowski, J; Maertens, J; Neufeld, EJ; Olivieri, N; Piga, A; Porter, J; Quarta, G; Rabault, B; Rose, C; Saglio, G; Soulières, D; Stadler, M; Tchernia, G; Vichinsky, E | 1 |
| Goldberg, SL | 1 |
| Ohyashiki, K | 1 |
23 review(s) available for deferasirox and Myelodysplastic Syndromes
| Article | Year |
|---|---|
[Transfusions in myelodysplastic syndromes].
Topics: Benzoates; Blood Grouping and Crossmatching; Combined Modality Therapy; Deferasirox; Erythrocyte Transfusion; Hematinics; Hemoglobins; Hepcidins; Humans; Intestinal Absorption; Iron Chelating Agents; Iron Overload; Iron, Dietary; Myelodysplastic Syndromes; Patient Satisfaction; Quality of Life; Rh Isoimmunization; Triazoles | 2017 |
Iron overload in myelodysplastic syndromes (MDS).
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Erythropoiesis; Hepcidins; Humans; Intestinal Mucosa; Iron; Iron Chelating Agents; Iron Overload; Liver; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2018 |
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Topics: Blood Transfusion; Deferasirox; Disease-Free Survival; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Survival Rate; Transfusion Reaction | 2018 |
Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Topics: Blood Transfusion; Chelation Therapy; Deferasirox; Disease Management; Humans; Iron Chelating Agents; Iron Overload; Liver Function Tests; Medication Adherence; Myelodysplastic Syndromes; Thalassemia; Treatment Outcome | 2018 |
Efficacy and safety of deferasirox in myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Clinical Trials, Phase II as Topic; Deferasirox; Drug Eruptions; Drug Therapy, Combination; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Multicenter Studies as Topic; Myelodysplastic Syndromes; NF-kappa B; Oxidative Stress; Prospective Studies; Retrospective Studies; Survival Analysis; Transfusion Reaction; Triazoles | 2013 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyridones; Triazoles | 2014 |
Deferasirox for managing iron overload in people with myelodysplastic syndrome.
Topics: Benzoates; Chelation Therapy; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2014 |
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.
Topics: Benzoates; Blood Platelets; Chelation Therapy; Deferasirox; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Leukocytes; Myelodysplastic Syndromes; Triazoles | 2015 |
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations.
Topics: Benzoates; Chelation Therapy; Deferasirox; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2015 |
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
Topics: Administration, Oral; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2009 |
Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
Topics: Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Platelet Transfusion; Treatment Outcome; Triazoles | 2009 |
Iron chelation therapy in MDS: what have we learnt recently?
Topics: Benzoates; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2009 |
Deferasirox for managing iron overload in people with myelodysplastic syndrome.
Topics: Benzoates; Chelation Therapy; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2010 |
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
Topics: Administration, Oral; Aged; Benzoates; Chelation Therapy; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Male; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles; Up-Regulation | 2011 |
[MDS].
Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles | 2012 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Phlebotomy; Pyridones; Siderophores; Transfusion Reaction; Triazoles | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles | 2013 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2006 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Survival Rate; Transfusion Reaction; Treatment Outcome; Triazoles | 2007 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
20 trial(s) available for deferasirox and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Cause of Death; Deferasirox; Double-Blind Method; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Patient Acuity; Progression-Free Survival; Transfusion Reaction; Young Adult | 2020 |
De-Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Blood Transfusion; Deferasirox; Disease-Free Survival; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate | 2020 |
Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan.
Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Deferasirox; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Skin Diseases; Taiwan | 2019 |
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.
Topics: Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Medication Adherence; Myelodysplastic Syndromes; Patient Reported Outcome Measures; Tablets; Thalassemia | 2019 |
Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Case-Control Studies; Cell Differentiation; Deferasirox; DNA Damage; Humans; Iron Chelating Agents; Iron Overload; Middle Aged; Myelodysplastic Syndromes; Oxidation-Reduction; Oxidative Stress; Prospective Studies; Reactive Oxygen Species; Stem Cells; Young Adult | 2019 |
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles | 2014 |
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2014 |
Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2015 |
Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Deferasirox; Humans; Iron Overload; Liver; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2015 |
CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chemistry, Pharmaceutical; Child; Deferasirox; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Quality of Life; Tablets, Enteric-Coated; Thalassemia; Triazoles; Young Adult | 2017 |
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Asian People; Benzoates; Blood Transfusion; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Japan; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2008 |
Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Topics: Aged; Aged, 80 and over; Benzoates; Bone Marrow; Deferasirox; Ferritins; Humans; Iron; Iron Overload; Liver; Magnetic Resonance Imaging; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Benzoates; Biomarkers; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Oxidative Stress; Time Factors; Treatment Outcome; Triazoles | 2010 |
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles; Young Adult | 2010 |
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2010 |
Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Topics: Aged; Antimicrobial Cationic Peptides; Benzoates; Blood Transfusion; Deferasirox; Erythropoiesis; Female; Hepcidins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Oxidative Stress; Transferrin; Triazoles | 2011 |
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Deferasirox; Female; Follow-Up Studies; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutrophils; Prognosis; Prospective Studies; Survival Rate; Transfusion Reaction; Triazoles; Young Adult | 2012 |
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Iron; Iron Chelating Agents; Male; Membrane Proteins; Middle Aged; Mutation; Myelodysplastic Syndromes; Prospective Studies; Time Factors; Treatment Outcome; Triazoles | 2012 |
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Creatinine; Deferasirox; Drug Eruptions; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
52 other study(ies) available for deferasirox and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Topics: Apoptosis; Benzoates; Deferasirox; Humans; Hydrazines; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia | 2022 |
Hypersensitivity Myocarditis Following Deferasirox Administration.
Topics: Aged; Biopsy; Deferasirox; Drug Hypersensitivity; Echocardiography; Electrocardiography; Female; Humans; Iron Chelating Agents; Magnetic Resonance Imaging, Cine; Myelodysplastic Syndromes; Myocarditis; Myocardium | 2022 |
Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia.
Topics: Anemia, Aplastic; Benzoates; Creatinine; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2022 |
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients.
Topics: Aged; Aged, 80 and over; Deferasirox; Erythropoiesis; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Regulatory Networks; Genome-Wide Association Study; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Transcriptome; Treatment Outcome | 2020 |
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome; Triazoles | 2017 |
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyridones; Retrospective Studies; Triazoles | 2018 |
Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome.
Topics: Aged; Benzoates; Biopsy; Deferasirox; Drug Eruptions; Female; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Triazoles; Urticaria; Vasculitis | 2017 |
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Transfusion; Deferasirox; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Young Adult | 2019 |
A case of late onset erythropoietic protoporphyria associated with myelodysplastic syndrome treated by the combination of beta carotene and azacitidine.
Topics: Aged; Azacitidine; Benzoates; beta Carotene; Deferasirox; Humans; Male; Myelodysplastic Syndromes; Protoporphyria, Erythropoietic; Triazoles | 2013 |
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles | 2013 |
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles | 2014 |
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?
Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles | 2013 |
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Republic of Korea; Transfusion Reaction; Triazoles | 2013 |
[The role of iron metabolism in myelodysplastic syndromes].
Topics: Anemia; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Triazoles | 2014 |
Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome.
Topics: Acute Disease; Administration, Oral; Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Red-Cell Aplasia, Pure; Triazoles | 2014 |
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Quality of Life; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2016 |
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Bone Marrow Cells; Cell Line; Cells, Cultured; Deferasirox; Deferoxamine; Gene Expression Regulation, Neoplastic; Humans; Iron Chelating Agents; Macrophages; Male; Mice; Myelodysplastic Syndromes; NF-kappa B; RNA, Long Noncoding; Transcription, Genetic; Triazoles; Tumor Necrosis Factor-alpha | 2015 |
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Medicare; Myelodysplastic Syndromes; Risk Reduction Behavior; Triazoles; United States | 2015 |
Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Follow-Up Studies; Hospitals, University; Humans; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2017 |
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.
Topics: Deferasirox; Deferoxamine; Hepatitis C; Humans; Hypertension, Portal; Iron Overload; Liver Cirrhosis; Male; Middle Aged; Myelodysplastic Syndromes | 2018 |
Acute interstitial nephritis due to deferasirox: a case report.
Topics: Acute Disease; Benzoates; Deferasirox; Drug Hypersensitivity; Eosinophils; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Nephritis, Interstitial; Triazoles | 2008 |
Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2008 |
Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2009 |
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Benzoates; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Triazoles | 2009 |
Iron chelation therapy in myelodysplastic syndrome - Cui bono?
Topics: Aged; Benzoates; Biomarkers; Chelation Therapy; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Life Expectancy; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2009 |
Adult-onset erythropoietic porphyria in the setting of MDS.
Topics: Aged, 80 and over; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Male; Myelodysplastic Syndromes; Porphyria, Erythropoietic; Triazoles | 2009 |
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Triazoles | 2010 |
Deferasirox (Exjade) for the treatment of iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Rare Diseases; Thalassemia; Triazoles | 2009 |
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.
Topics: Aged; Anemia; Benzoates; Chronic Disease; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Radiography; Thrombocytopenia; Transfusion Reaction; Triazoles | 2010 |
Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients.
Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; Deferasirox; Female; Hematopoiesis; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2010 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Quality-Adjusted Life Years; Siderophores; Treatment Outcome; Triazoles | 2010 |
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
Topics: Aged; Aged, 80 and over; Apoptosis; Benzoates; Blotting, Western; Deferasirox; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Iron; Iron Chelating Agents; K562 Cells; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; NF-kappa B; Protein Binding; Reactive Oxygen Species; Triazoles | 2010 |
Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.
Topics: Benzoates; Blood Transfusion; Deferasirox; Erythroid Cells; Ferritins; Hemoglobins; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2010 |
Delineating parameters of iron overload in MDS patients treated with deferasirox.
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2010 |
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Insurance Claim Review; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Siderophores; State Medicine; Survival Analysis; Triazoles; United Kingdom | 2010 |
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles | 2010 |
Deferasirox increases BU blood concentrations.
Topics: Benzoates; Busulfan; Deferasirox; Female; Humans; Immunosuppressive Agents; Iron Chelating Agents; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Triazoles | 2012 |
Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.
Topics: Benzoates; Chelation Therapy; Deferasirox; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Practice Guidelines as Topic; Triazoles | 2011 |
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles | 2012 |
Severe hypocalcemia and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome under deferasirox therapy for myelodysplasic syndrome.
Topics: Aged; Benzoates; Deferasirox; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Female; Humans; Hypocalcemia; Iron Chelating Agents; Myelodysplastic Syndromes; Syndrome; Triazoles | 2012 |
[Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes].
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2012 |
Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.
Topics: Aged; Aged, 80 and over; Benzoates; Cell Proliferation; Cell Survival; Cells, Cultured; Deferasirox; Down-Regulation; Female; Fetal Blood; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Reactive Oxygen Species; Triazoles; Up-Regulation | 2012 |
First report of drug-induced esophagitis by deferasirox.
Topics: Benzoates; Deferasirox; Esophagitis; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2012 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS.
Topics: Benzoates; Cell Proliferation; Deferasirox; Female; Hematopoietic Stem Cells; Humans; Male; Myelodysplastic Syndromes; Reactive Oxygen Species; Triazoles | 2012 |
Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Antigens, CD; Benzoates; Case-Control Studies; Deferasirox; Deoxyguanosine; DNA Damage; Erythrocyte Transfusion; Ferritins; Genome, Human; Humans; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Prospective Studies; Reactive Oxygen Species; Statistics, Nonparametric; Triazoles | 2012 |
[Transfusion reaction and HLA antibodies].
Topics: Acute Lung Injury; Antibody Formation; Benzoates; Blood Transfusion; Deferasirox; Hematologic Neoplasms; Hemochromatosis; HLA Antigens; Humans; Iron Chelating Agents; Isoantibodies; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2012 |
Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Cell Count; Cell Proliferation; Cohort Studies; Deferasirox; Erythroid Precursor Cells; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2013 |
Iron chelation therapy for myelodysplastic syndrome: if and when.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Survival Rate; Triazoles | 2006 |
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Diamond-Blackfan; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles | 2008 |